Sino Biological: Tumor necrosis factors (TNFs) and their receptors (TNFRs) are key immune regulators. Dysregulation of TNFs/TNFRs is linked to cancer progression, making them critical targets for immunotherapy and drug development.
Tumor necrosis factors (TNFs) and their corresponding receptors (TNFRs) play crucial roles in regulating the immune system. Dysregulation of TNFs/TNFRs is closely linked to tumorigenesis, progression, invasion, and metastasis. Thus, there has been an upsurge of interest in targeting TNFs/TNFRs for cancer immunotherapy in recent years.
The FDA has approved five medicines that target BCMA for myeloma as of January 2024. An antibody-drug conjugate (ADC) targeting CD30, Brentuximab vedotin, has also been approved by the FDA to specifically target mesenchymal large-cell lymphoma and Hodgkin’s lymphoma.
TNFs also frequently target TNFRs such as 4-1BB, Fas/CD95, and GITR, while other targets include RANKL, TRAIL, BLys, and CD40L. Drugs that target these TNFs/TNFRs are either authorized for clinical use already or are undergoing clinical trials.
Sino Biological offers a comprehensive selection of recombinant TNF and TNFR proteins and corresponding antibodies that support drug discovery and development research on TNFs/TNFRs.
TNF receptor superfamily targeted therapy in cancer
TNFRSF molecules and ligands are targeted on cells of the immune system to boost immune activity against a tumor cell or on tumor cells to either directly promote apoptotic cell death or focus cytotoxic mechanisms toward a tumor cell.
SPR assay: Captured Adalimumab on Anti-human IgG Fc via CM5 Chip binds to TNF-α with an affinity constant of 0.2843 nM. Image Credit: Sino Biological Inc.
Direct contact technical support
Find products for your research
